Loading issue research
Fund aging biology for longer healthy life, with rigorous trials, usable biomarkers, and enforcement against unsupported anti-aging claims.
Verification Status
AI-researched, unverifiedLast Reviewed
Jul 12, 2026
Cited Sources
9
What is failing, what we would change, and the conclusion we are willing to defend.
The old title, "Life Extension Research," points at a real field but the wrong promise. The defensible public goal is healthspan: more years with preserved function, fewer years lost to frailty, disability, chronic disease, and dependence. The National Institute on Aging exists to study aging and extend healthy, active years of life. ARPA-H's PROSPR program is already aimed at the practical bottleneck: biomarkers, intrinsic-capacity measures, and clinical trial protocols that can test age-related functional outcomes within years. Lifespan results take decades.
That is a serious research agenda. It is not permission to launder anti-aging clinics, supplement claims, stem-cell marketing, plasma hype, or genetic shortcuts into public policy. FDA and FTC evidence standards require especially strong enforcement because older adults and families facing decline are easy targets for expensive false hope.
Fund NIH, NIA, and ARPA-H work on geroscience, healthspan biomarkers, intrinsic-capacity measures, age-related disease mechanisms, and trial designs that can test preserved function in realistic time frames.
Support public data infrastructure for longitudinal aging research, with consent, privacy, cybersecurity, and data-access rules aligned with PRIV-01. Commercial health-data extraction receives no blank permission slip.
Keep FDA's approval standard and FTC's advertising standard intact. A product marketed to treat age-related loss of function should prove it like a health product. Wellness language cannot evade that standard.
Require federally funded healthspan trials to measure functional outcomes that matter: mobility, cognition, immune function, resilience, frailty, independence, and adverse events. Omics proxies alone cannot establish benefit.
Build access into the research plan early. If a healthspan intervention works, public policy should not let it become a longevity luxury good available only to wealthy early adopters.
The party should be ambitious here because aging biology is real science. It should also be disciplined because this is exactly the field where ambition turns into grift when evidence is treated as optional.
Turn frustration into useful pressure.
If this position misses evidence or a lived consequence, challenge it. If it holds up, help test it locally and connect it to the issues around it.